Gastric carcinoid tumor (gastric neuroendocrine neoplasm/NET) is a neuroendocrine tumor originating from enterochromaffin-like (ECL) cells in the gastric mucosa. It constitutes 1-2% of all gastric tumors and 8.7% of all gastrointestinal carcinoids. Three types exist: Type I (70-80%) — develops on chronic atrophic gastritis (autoimmune/pernicious anemia), multiple, small (<1 cm), located in gastric fundus/body, elevated gastrin, excellent prognosis. Type II (5-10%) — Zollinger-Ellison syndrome/MEN1 associated, multiple, small-to-medium, elevated gastrin, intermediate prognosis. Type III (15-20%) — sporadic, solitary, large (>2 cm), any location, normal gastrin, aggressive, poor prognosis. CT and endoscopic US are used for evaluation. Type I and II are generally treated with endoscopic resection, while Type III requires surgical resection and systemic therapy.
Age Range
35-75
Peak Age
55
Gender
Female predominant
Prevalence
Rare
Gastric carcinoid tumors originate from ECL cells. Pathophysiological mechanism in Type I: chronic atrophic gastritis → parietal cell loss → achlorhydria → loss of negative feedback → excessive gastrin secretion from G cells (hypergastrinemia) → gastrin trophically stimulates ECL cells → ECL cell hyperplasia → dysplasia → carcinoid tumor development. This sequence develops as a result of years of chronic hypergastrinemia. In Type II, the gastrinoma in ZES directly produces hypergastrinemia and triggers the same ECL proliferation sequence. Type III develops sporadically, is not related to hypergastrinemia — malignant transformation occurs through de novo genetic mutations (TP53, RB1, DAXX/ATRX). Pathophysiological basis of imaging findings: Type I/II lesions appear as small, well-defined, submucosal nodules because ECL cell proliferation begins at the mucosa/submucosa boundary and grows slowly. Type III shows aggressive growth — extends beyond muscularis propria, forms a larger mass with heterogeneous enhancement and possible necrosis.
Multiple small (<1 cm) hypervascular submucosal polyps in gastric fundus/body on atrophic gastritis background (thin mucosa, hypergastrinemia) = Type I gastric carcinoid. Pernicious anemia association strengthens the diagnosis. This pattern is specific to Type I and constitutes 70-80% of gastric carcinoids.
In the arterial phase, gastric carcinoid tumors appear as hypervascular submucosal nodule(s). Type I/II: multiple small (<1 cm), well-defined, intensely enhancing nodules in fundus/body mucosa — often difficult to see on CT and better detected by endoscopy/EUS. Type III: solitary, large (>2 cm), intensely or heterogeneously enhancing mass at any location — central necrosis may be seen in large masses. Intense arterial enhancement is characteristic of all types because NETs have a rich vascular network.
Report Sentence
In the gastric fundus/body mucosa, ___ intensely enhancing submucosal nodules are seen in the arterial phase (largest ___ mm); consistent with Type I gastric carcinoid with atrophic gastritis findings.
In the portal venous phase, Type III gastric carcinoid appears as a solitary, large (>2 cm) mass. Enhancement may be heterogeneous — may contain central necrosis, cystic areas. May extend beyond muscularis propria to the serosal surface. Liver metastases appear as hypervascular lesions — multiple hepatic lesions with intense arterial enhancement and portal venous washout. Perigastric and mesenteric lymphadenopathy may accompany. The aggressive behavior of Type III manifests with metastatic disease findings on CT.
Report Sentence
A heterogeneously enhancing mass measuring approximately ___ cm in the gastric ___ region is seen with multiple hypervascular liver lesions; consistent with Type III gastric carcinoid and liver metastases.
On endoscopic ultrasound (EUS), gastric carcinoid tumor appears as a submucosal hypoechoic, well-defined, homogeneous nodule. EUS clearly distinguishes wall layers: the lesion usually originates from the second (deep mucosa) or third layer (submucosa). Muscularis propria (fourth layer) integrity is critical for invasion assessment — intact muscularis propria indicates local disease. Type I/II lesions appear as small (<10 mm), multiple, submucosal nodules in the gastric body. Type III lesions are larger, solitary, and may extend beyond the muscularis propria.
Report Sentence
On endoscopic US, ___ submucosal, hypoechoic, well-defined nodules are seen in the gastric body/fundus region (largest ___ mm); muscularis propria is intact.
Most gastric carcinoid tumors express somatostatin receptors (especially SSTR2). They show positive uptake on octreotide scintigraphy (In-111 DTPA-octreotide/Octreoscan) or Ga-68 DOTATATE PET/CT. Ga-68 DOTATATE PET/CT is superior to octreotide scintigraphy — higher sensitivity and spatial resolution. Used for metastatic disease detection, staging, and treatment planning. Determines candidacy for Lu-177 DOTATATE (PRRT — peptide receptor radionuclide therapy).
Report Sentence
Somatostatin receptor positive lesions are seen in the gastric wall and liver on Ga-68 DOTATATE PET/CT; consistent with neuroendocrine tumor.
On MRI, gastric carcinoid tumor appears as a mildly hyperintense nodule on T2, isointense on T1 as a submucosal nodule. May show restricted diffusion on DWI. Intense arterial enhancement is characteristic on contrast-enhanced series. MRI is particularly valuable for detecting liver metastases — hepatocyte-phase contrast MRI (gadoxetic acid) better detects small metastases.
Report Sentence
On MRI, a T2 mildly hyperintense, T1 isointense submucosal nodule is seen in the gastric wall with intense arterial enhancement; consistent with neuroendocrine tumor.
Criteria
On chronic atrophic gastritis/pernicious anemia, multiple, small (<1 cm), in fundus/body. Hypergastrinemia, low acid. 70-80%.
Distinct Features
Excellent prognosis, metastasis very rare (<5%). Endoscopic polypectomy sufficient. Annual endoscopy follow-up.
Criteria
On ZES/MEN1 background, multiple, small-medium, in gastric body. Duodenal/pancreatic gastrinoma accompanies. 5-10%.
Distinct Features
Intermediate prognosis, metastasis risk 10-30%. Endoscopic/surgical approach combined with gastrinoma treatment. MEN1 syndrome screening needed.
Criteria
Sporadic, solitary, large (>2 cm), any location. Normal gastrin, normal acid. 15-20%.
Distinct Features
Poor prognosis, metastasis risk >50% (liver, lymph nodes). Surgical resection + systemic chemotherapy/PRRT. 5-year survival 50%.
Distinguishing Feature
GIST originates from muscularis propria (4th layer); carcinoid from mucosa/submucosa (2nd-3rd layer). Origin layer on EUS is distinguishing. GIST usually single and large.
Distinguishing Feature
Adenocarcinoma mucosal irregularity, wall thickening, infiltrative; carcinoid submucosal, well-defined, hypervascular. Adenocarcinoma usually hypovascular.
Distinguishing Feature
Lymphoma diffuse wall thickening, submucosal spread, hypovascular; carcinoid focal nodular, hypervascular. Large spleen and LAP may accompany lymphoma.
Distinguishing Feature
Fundic gland polyps small, multiple, in fundus; carcinoid also multiple in fundus but distinguished by hypervascular enhancement and hypergastrinemia. Neuroendocrine markers negative in polyps.
Urgency
routineManagement
surgicalBiopsy
NeededFollow-up
12-monthManagement of gastric carcinoid tumor varies by type. Type I: endoscopic polypectomy and annual follow-up endoscopy are sufficient; surgery considered if >10 mm or muscularis propria invasion. Type II: endoscopic/surgical approach combined with gastrinoma treatment (surgical/medical). Type III: wide surgical resection + lymphadenectomy; somatostatin analogs, chemotherapy, or PRRT (Lu-177 DOTATATE) for metastatic disease. Ga-68 DOTATATE PET/CT is used for staging and follow-up in all types.
Type 1 gastric carcinoids have good prognosis and endoscopic surveillance/resection is sufficient. Type 3 sporadic carcinoids are aggressive, require surgery, and have high risk of liver metastasis.